Supplemental ferulic acid does not affect metabolic markers and improves some oxidative damage parameters in diabetic rats

This study investigated the differences in health outcomes associated with ferulic acid (FA) supplementation in animals before the induction of diabetes with streptozotocin (STZ) treatment and post-STZ treatment. 18 male Wistar rats were equally distributed into three groups: groups 1 and 2 received FA (50 mg/kg body weight) supplementation one week before STZ treatment (60 mg/kg body weight, intraperitoneal) and one week after STZ treatment, respectively; group 3 received STZ without FA supplementation. FA supplementation was continued for 12 weeks after STZ treatment. The results indicated no difference in glucose and lipid profile with FA supplementation. However, FA supplementation reduced lipid and protein oxidative damage in the heart, liver and pancreas and increased glutathione in the pancreas. The results indicate that while oxidative damages were positively affected by FA, it was not sufficient to improve metabolic markers of diabetes.

Automated summary

This study investigated the differences in health outcomes associated with ferulic acid (FA) supplementation in animals before and after streptozotocin (STZ) treatment for diabetes. The results showed that FA supplementation did not affect glucose and lipid profile, but it reduced lipid and protein oxidative damage in the heart, liver, and pancreas, and increased glutathione levels in the pancreas. However, FA supplementation was not sufficient to improve metabolic markers of diabetes.